Tvardi develops oral small molecule drugs that inhibit STAT3 to treat inflammatory and proliferative diseases. It last closed at $1.01 on Nov 17, down 8.18% on the day.
Only 1 firm rated TVRD in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 1286.1% upside
Based on 1 analyst who set a price target on TVRD in the past 90 days. The average target is $14.00, with a high of $14.00 and a low of $14.00, compared with the last close of $1.01.
Low $14.00Avg $14.00High $14.00
Blue marker: last close $1.01
Highest target$14.00
Average target$14.00
Lowest target$14.00
Latest rating changes
LUCID CAPITAL MARKETSAssumed coverage
Sep 8Buy$14
BTIGTarget lowered
Jul 30Buy$15 → $5
Raymond JamesUpgrade
Jul 8Buy$10
BTIGReiterated
Jul 7Buy$15
HC Wainwright & Co.Initiated
Jun 8Buy$9
Date
Firm
Action
Rating
Price target
Sep 8
LUCID CAPITAL MARKETS
Assumed coverage
Buy
$14
Jul 30
BTIG
Target lowered
Buy
$15 → $5
Jul 8
Raymond James
Upgrade
Buy
$10
Jul 7
BTIG
Reiterated
Buy
$15
Jun 8
HC Wainwright & Co.
Initiated
Buy
$9
Loading…
Technical Analysis
TVRD · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 154% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot S1 at $0.98, and the nearest resistance the Pivot at $1.03.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 14.9%/day
Key levels
$5.6952 week high+463.4%
$2.56200 day average+153.5%
$1.74100 day average+72.3%
$1.2050 day average+18.8%
$1.09Swing high (Oct 21)+7.9%
$1.06Pivot R1+5.0%
$1.03Pivot+2.0%
$1.0120 day average+0.0%
$1.01Last close
$0.98Pivot S1−3.0%
$0.97Swing low (Oct 12)−4.0%
$0.7752 week low−23.8%
Indicators
RSI (14)
45.53
Middle of its range
Neutral
MACD
0.00
Above its signal line
Bullish
Stochastic
38.7
Middle of its range
Neutral
ADX (14)
37.7
Trending up
Williams %R
-71.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
6.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+21.0%
Change over 10 sessions
Bullish
ATR (14)
$0.15
Typical daily range, 14.9% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityHigh, 54.0%/day
Key levels
$5.6952 week high+463.4%
$2.56200 day average+153.5%
$1.74100 day average+72.3%
$1.2050 day average+18.8%
$1.09Swing high (Oct 21)+7.9%
$1.06Pivot R1+5.0%
$1.03Pivot+2.0%
$1.0120 day average+0.0%
$1.01Last close
$0.98Pivot S1−3.0%
$0.97Swing low (Oct 12)−4.0%
$0.7752 week low−23.8%
Indicators
RSI (14)
34.94
Weak, oversold below 30
Neutral
MACD
-0.82
Above its signal line
Bullish
Stochastic
21.8
Middle of its range
Neutral
ADX (14)
12.0
No clear trend
Williams %R
-80.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-76.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−46.0%
Change over 10 sessions
Bearish
ATR (14)
$0.55
Typical daily range, 54.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100–
MA 200–
What happened before, for TVRD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TVRD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in TVRD in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVRD is in one of them and how their past TVRD trades turned out.
Tvardi is a biopharmaceutical company based in Sugar Land, Texas. It is developing oral, small molecule drugs that aim to block STAT3, a protein inside cells that drives inflammatory and cell growth diseases. Its TTI-101 candidate is being tested in patients with liver cancer and has also been studied in idiopathic pulmonary fibrosis, a lung disease. The company does not yet sell products, and its drugs are still in clinical trials.